CryoPort (CYRX) Stock Forecast & Price Target

CryoPort is benefiting from a clear inflection in its core Life Sciences Services business, which grew 15% year over year on $49 million of 2Q:26 revenue and helped drive its first positive adjusted EBITDA since 1Q:23, alongside about $5 million of positive operating cash flow in 1H 2026. The company’s outlook is strengthened by its leadership in cell and gene therapy logistics, with support for 22 approved commercial therapies, 779 clinical trials, and 94 Phase 3 programs, creating a growing annuity-like revenue base as therapies commercialize. Additional upside comes from higher-margin bio-storage and bio-services, the Fusion freezer that expands access beyond major hospitals, and new Paris and Santa Ana facilities that should support further scale and margin expansion.

CryoPort is exposed to a fragile operating model in which a single shipment failure, product recall, or supply-chain disruption can destroy sensitive biologics, trigger litigation, and damage customer trust, while its proprietary Cryoportal dependence on a third party adds another execution risk. The company also faces a long adoption cycle, since switching providers in a highly regulated life sciences market requires extensive auditing and qualification that can take several months, delaying revenue conversion and making growth less predictable. Its outlook is further pressured by intense competition, global regulatory complexity, and APCA’s slowdown in demand for MVE freezers, while the bear case assumes fewer-than-expected cell and gene therapy approvals would slow revenue growth and weigh on margins and profitability.